SystImmune to Present New BL-B01D1 Data at ESMO 2024

SystImmune, Inc., a clinical-stage biotechnology company, has announced that three significant abstracts on BL-B01D1, a promising EGFRxHER3 bispecific antibody-drug conjugate (ADC), will be presented at the European Society for Medical Oncology (ESMO) Congress 2024. The congress will take place from September 13 to 17 in Barcelona, Spain. BL-B01D1 is being developed collaboratively by SystImmune and Bristol Myers Squibb under a special license and partnership agreement.

The upcoming presentations will include expanded results from clinical trials involving patients with advanced Urothelial Carcinoma (UC), Biliary Tract Carcinoma (BTC), and Esophageal Squamous Cell Carcinoma (ESCC). These patients have undergone multiple cycles of prior therapies. The data to be showcased highlight the ongoing progress in the clinical development of BL-B01D1, building on previously reported clinical data in lung and breast cancer patients at major oncology conferences such as ASCO, ESMO, and SABCS in 2023.

Jonathan Cheng, M.D., Chief Medical Officer of SystImmune, commented on the significance of these findings, stating, "These data support our continued conviction that BL-B01D1 has a manageable safety profile and add to the body of evidence that shows encouraging signals of efficacy across a wide variety of tumors. This positions BL-B01D1 as a versatile therapeutic option that may address the unmet medical needs of patients with limited treatment options. We are committed to advancing this therapy through clinical trials, exploring its potential not only as a monotherapy but also in combination with other agents, to improve outcomes for cancer patients globally."

The details of the presentations at ESMO are as follows:

- BL-B01D1 in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC):
- Session Title: Proffered paper session 1: GU tumors, non-prostate
- Presentation Number: 19590
- Speaker: Dingwei Ye (Shanghai, China)
- Session Date & Time: Friday, September 13th, 2024, 2:00 PM-3:30 PM CEST

- BL-B01D1 in Patients with Locally Advanced or Metastatic Biliary Tract Carcinoma (BTC):
- Presentation Number: 54P
- Speaker: Zhihao Lu (Beijing, China)
- Onsite Poster display date: Monday, September 16th, 2024

- BL-B01D1 in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC):
- Presentation Number: 1426P
- Speaker: Liu Chang (Beijing, China)
- Onsite Poster display date: Monday, September 16th, 2024

BL-B01D1 is a bispecific ADC that targets both EGFR and HER3, proteins highly expressed in most epithelial tumors. It has two binding domains for different Growth Factor Receptors, which are crucial for cancer cell proliferation and survival. The mechanism of action involves blocking signals from EGFR and HER3 to cancer cells, reducing their proliferation and survival. Once internalized by the cancer cells, BL-B01D1 is trafficked to the lysosomes where it releases its therapeutic payload, inducing genotoxic stress and activating pathways that lead to cancer cell death.

SystImmune, headquartered in Redmond, WA, is a clinical-stage biopharmaceutical company focusing on developing innovative cancer treatments. The company utilizes its established drug development platforms to create bi-specific and multi-specific antibodies, as well as ADCs. SystImmune has several assets in various stages of clinical trials for both solid tumors and hematologic indications. Alongside ongoing clinical trials, the company has a robust preclinical pipeline of potential cancer therapeutics in discovery or IND-enabling stages, representing cutting-edge biologics development.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!